FRUQUIN 5 mg (Fruquintinib): Uses, Dosage & Side Effects
FRUQUIN 5 mg (Fruquintinib): Uses, Dosage, Side Effects & Colorectal Cancer Treatment
What Is FRUQUIN 5 mg?
FRUQUIN 5 mg contains fruquintinib, an oral kinase inhibitor that targets vascular endothelial growth factor receptors, commonly referred to as VEGFRs.
Cancer cells need access to nutrients and oxygen to continue growing. One way tumours support this process is by stimulating the formation of new blood vessels, a biological process known as angiogenesis.
Fruquintinib interferes with signalling through VEGF receptors. By inhibiting this pathway, it can reduce the tumour's ability to develop and maintain the blood-vessel network that supports cancer growth.
Fruquintinib is primarily used in the treatment of metastatic colorectal cancer (mCRC). In the EU, the approved indication covers adults with metastatic colorectal cancer who have previously received standard treatments including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, as well as anti-VEGF and anti-EGFR therapy, and whose disease has progressed on or who are intolerant to trifluridine/tipiracil or regorafenib.
The product information supplied for this page is:
- Product Name: FRUQUIN 5 mg
- Generic Name: Fruquintinib
- Strength: 5 mg
- Dosage Form: Capsule
- Pack Size: 21 Capsules
Fruquintinib is a prescription oncology medicine and should be prescribed and monitored by an appropriately qualified healthcare professional.
What Is Fruquintinib Used For?
Metastatic Colorectal Cancer
Fruquintinib is used for adults with metastatic colorectal cancer, meaning colorectal cancer that has spread to distant parts of the body.
It is generally used after patients have already received several standard anticancer treatments.
Patient-Friendly Explanation
When colorectal cancer becomes metastatic and continues progressing despite previous treatments, additional treatment options may be considered.
Fruquintinib works differently from conventional chemotherapy. Instead of directly targeting rapidly dividing cells, it blocks VEGF receptor signalling involved in the formation of blood vessels that support tumour growth.
Medical Explanation
Fruquintinib is a selective inhibitor of VEGFR-1, VEGFR-2 and VEGFR-3. These receptors are important mediators of angiogenic signalling. Inhibition of VEGFR signalling reduces tumour-associated angiogenesis and can interfere with the vascular support required for tumour progression.
How Does Fruquintinib Work?
Tumour growth requires more than cancer-cell multiplication. As a tumour becomes larger, it needs an adequate blood supply to obtain oxygen and nutrients.
Tumour cells can stimulate surrounding tissues to form new blood vessels by releasing angiogenic signals, including vascular endothelial growth factor (VEGF).
VEGF activates receptors on endothelial cells. These receptors then transmit intracellular signals that promote:
- Blood-vessel growth
- Endothelial-cell proliferation
- Vascular survival
- Tumour-associated angiogenesis
A simplified pathway is:
Tumour signalling → VEGF activation → VEGFR signalling → new blood-vessel formation → tumour support
Fruquintinib interferes with this pathway:
Fruquintinib → VEGFR-1/2/3 inhibition → reduced angiogenic signalling → reduced tumour vascular support
The purpose is not to directly destroy every cancer cell. Instead, fruquintinib targets an important biological process that tumours use to sustain growth.
This mechanism makes fruquintinib a targeted anti-angiogenic therapy.
Because it acts on vascular signalling, treatment can also produce effects related to blood pressure, bleeding, wound healing and other vascular processes. This is why clinical monitoring is important during therapy.
Key Indications
Fruquintinib is used for eligible adults with:
- Metastatic colorectal cancer
- Previously treated advanced colorectal cancer
- Disease that has progressed after specified standard treatments
- Patients who meet the applicable regulatory treatment criteria
In the EU, the indication specifically includes patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and anti-VEGF and anti-EGFR agents, with progression or intolerance to trifluridine/tipiracil or regorafenib.
FRUQUIN 5 mg Dosage & Administration
The standard fruquintinib regimen used in current regulatory information is:
5 mg once daily for 21 consecutive days, followed by 7 days without treatment, creating a 28-day treatment cycle.
With a 5 mg capsule, this corresponds to one 5 mg dose on each treatment day unless the prescribing physician has modified the regimen.
How to Take Fruquintinib
- Take it exactly as prescribed.
- Take the dose once daily.
- Follow the 21-days-on / 7-days-off cycle.
- Take it at approximately the same time each day.
- Swallow the capsule according to the product instructions.
- Do not change the dose without medical advice.
If significant adverse effects occur, the treating physician may interrupt treatment, reduce the dose or discontinue treatment.
Missed Dose
If a dose is missed, patients should follow the instructions in their local product information or from their oncology team.
Do not take an extra dose to compensate for a missed dose unless specifically instructed by a healthcare professional.
Fruquintinib Side Effects
Like other targeted anticancer medicines, fruquintinib can cause adverse reactions.
Important reactions reported with fruquintinib include:
- Hypertension
- Hand-foot syndrome
- Proteinuria
- Diarrhea
- Fatigue
- Decreased appetite
- Voice changes
- Stomatitis
- Weight loss
- Bleeding-related events
- Abnormal liver-function tests
The frequency and severity of adverse reactions can vary between patients.
Common Side Effects
Patients receiving fruquintinib may experience:
High Blood Pressure
Fruquintinib can increase blood pressure. Blood-pressure monitoring is therefore important during treatment.
Hand-Foot Syndrome
Redness, swelling, tenderness or discomfort affecting the palms and soles can occur.
Fatigue
Some patients experience tiredness or reduced energy during treatment.
Diarrhea
Diarrhea can occur and may require supportive treatment if persistent or severe.
Reduced Appetite
Changes in appetite can occur during therapy and may contribute to weight loss.
Voice Changes
Dysphonia or changes in voice quality are among the recognized adverse effects.
Serious Side Effects
Important serious or clinically significant risks include:
- Severe hypertension
- Serious bleeding
- Gastrointestinal perforation
- Fistula formation
- Poor wound healing
- Proteinuria
- Liver injury
- Arterial or venous thromboembolic events
- Posterior reversible encephalopathy syndrome in rare cases
The FDA prescribing information specifically warns about hypertension, hemorrhage, infections, gastrointestinal perforation and fistula formation, proteinuria, impaired wound healing and reversible posterior leukoencephalopathy syndrome.
When to Seek Medical Attention
Seek prompt medical assessment for:
- Severe or persistent headache with neurological symptoms
- Very high blood pressure symptoms
- Significant or unexplained bleeding
- Severe abdominal pain
- Persistent vomiting or diarrhea
- Severe swelling or painful skin changes
- Sudden weakness, confusion or visual changes
- Signs of infection
- New severe symptoms around the time of surgery
Warnings & Precautions
Blood Pressure
Blood pressure should be controlled before and monitored during treatment. Fruquintinib can cause hypertension.
Bleeding Risk
Anti-angiogenic therapy can increase the risk of hemorrhage. Patients with existing bleeding problems should inform their healthcare professional before treatment.
Wound Healing
Fruquintinib can interfere with normal wound healing. The FDA prescribing information recommends stopping treatment at least 2 weeks before planned surgery and restarting only when adequate wound healing has occurred and according to the treating physician's assessment.
Gastrointestinal Complications
Gastrointestinal perforation and fistula formation are important but uncommon risks requiring urgent evaluation when severe abdominal symptoms develop.
Kidney Considerations
Proteinuria can occur during treatment. Urine protein monitoring may therefore be appropriate.
Liver Considerations
Liver function should be monitored when clinically appropriate, particularly in patients with pre-existing hepatic problems.
Drug Interactions
Patients should provide their healthcare professional with a complete list of medicines and supplements.
This includes:
- Prescription medicines
- Over-the-counter products
- Vitamins
- Herbal products
- Traditional medicines
- Other cancer medicines
Fruquintinib is metabolized primarily through CYP3A4, with additional involvement of other metabolic pathways. Medicines that substantially alter these pathways may affect fruquintinib exposure, so interaction review is important.
Do not start a new medicine or supplement without checking with the treating healthcare professional.
Food Considerations
Fruquintinib can be administered orally according to the prescribed schedule. Patients should follow the administration instructions supplied with their specific product.
Avoid making major changes to supplements or herbal products without discussing them with the oncology team.
Pregnancy & Breastfeeding
Fruquintinib may cause fetal harm.
Women who could become pregnant should discuss appropriate contraception with their healthcare professional before treatment.
Pregnancy should be avoided during therapy and for the period specified by the applicable local prescribing information after treatment.
Breastfeeding is generally not recommended during treatment because of the potential risk to a breastfed infant.
Special Populations
Elderly Patients
Older adults may receive fruquintinib when clinically appropriate. Treatment should consider overall health, nutritional status, blood pressure, kidney function and concurrent medicines.
Pediatric Patients
Fruquintinib is not established as a routine pediatric treatment for metastatic colorectal cancer. The FDA states that its safety and effectiveness in children have not been established.
Renal Impairment
Patients with kidney disease should inform their healthcare professional before treatment. Proteinuria and other renal complications may require monitoring.
Hepatic Impairment
Liver function and the severity of hepatic impairment should be considered when determining whether and how fruquintinib should be used.
Storage Instructions
Store FRUQUIN according to the storage conditions specified on the product packaging.
General precautions:
- Keep the capsules in their original packaging.
- Keep away from children.
- Protect from inappropriate heat and moisture.
- Do not use expired capsules.
- Do not use damaged or compromised capsules.
- Follow the product-specific storage instructions supplied with the medicine.
Frequently Asked Questions
1. What is FRUQUIN 5 mg used for?
FRUQUIN 5 mg contains fruquintinib and is used for eligible adults with previously treated metastatic colorectal cancer.
2. What is Fruquintinib?
Fruquintinib is an oral kinase inhibitor that targets VEGF receptors involved in tumour angiogenesis.
3. How does Fruquintinib work?
It blocks VEGFR signalling, reducing signals that promote formation of blood vessels supplying tumours.
4. What type of cancer does Fruquintinib treat?
Its established indication is metastatic colorectal cancer in appropriately selected adults.
5. What is the standard Fruquintinib dose?
The standard regimen is 5 mg once daily for 21 days followed by 7 days without treatment in a 28-day cycle.
6. Is Fruquintinib a chemotherapy medicine?
Fruquintinib is a targeted kinase inhibitor rather than conventional cytotoxic chemotherapy.
7. Can Fruquintinib lower tumour growth?
Its anti-angiogenic mechanism can interfere with the blood-vessel support required for tumour growth and progression.
8. What are common Fruquintinib side effects?
Important reported effects include hypertension, hand-foot syndrome, diarrhea, fatigue, decreased appetite, proteinuria and voice changes.
9. Can Fruquintinib cause high blood pressure?
Yes. Hypertension is an important adverse effect and blood pressure should be monitored during treatment.
10. Can Fruquintinib cause hand-foot syndrome?
Yes. Hand-foot syndrome is a recognized adverse reaction and may require supportive care or treatment adjustment.
11. Does Fruquintinib increase bleeding risk?
Bleeding is a recognized risk, particularly in patients with additional risk factors.
12. Can Fruquintinib affect wound healing?
Yes. Because it targets angiogenesis, it can impair wound healing. Planned surgery requires careful treatment planning.
13. Is Fruquintinib used after other colorectal cancer treatments?
Yes. Regulatory indications specify use after previous standard treatments in appropriately selected patients with metastatic colorectal cancer.
14. Can children take Fruquintinib?
Safety and effectiveness have not been established in children under the FDA-approved indication.
15. Is FRUQUIN 5 mg a prescription medicine?
Fruquintinib is a prescription oncology medicine and should be used under appropriate specialist supervision.
Global Medicine Information & Support by RootAid Pharma
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides educational medicine information and international pharmaceutical support for individuals and organizations seeking information about prescription and specialty medicines.
Our educational resources cover areas such as:
- Oncology medicines
- Colorectal cancer treatments
- Targeted cancer therapies
- Specialty medicines
- Prescription medicine information
- Treatment and safety education
- International medicine information
- Pharmaceutical support resources
For medicines such as fruquintinib, treatment suitability depends on the patient's diagnosis, previous treatment history, medical condition and the prescribing requirements applicable in their country.
RootAid Pharma does not claim to manufacture FRUQUIN or fruquintinib. Availability, prescription requirements, import regulations and supply conditions can vary internationally.
Medical Disclaimer
This article is intended for general educational and informational purposes only. It does not replace a physician's diagnosis, individualized treatment plan, official prescribing information or professional medical advice.
Fruquintinib is a prescription anticancer medicine intended for appropriately selected patients with metastatic colorectal cancer. Treatment selection, dosage, monitoring, dose modification and treatment duration must be determined by a qualified healthcare professional.
Approved indications and prescribing recommendations can differ between countries and may change over time. Patients should follow the official medicine information applicable in their country.
Do not start, stop or change Fruquintinib treatment without medical supervision.
Sources: EMA and FDA prescribing information were used to verify the indication, mechanism, dosing schedule and major safety information.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.